Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Moleculin Biotech ( (MBRX) ) has provided an announcement.
On June 27, 2025, Moleculin Biotech, Inc. received a deficiency letter from Nasdaq indicating that its stock price had fallen below the $1.00 minimum requirement for 30 consecutive business days. The company has until December 24, 2025, to regain compliance or risk delisting, with potential measures including a reverse stock split.
The most recent analyst rating on (MBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Average Trading Volume: 1,845,008
Technical Sentiment Signal: Sell
Current Market Cap: $7.1M
For a thorough assessment of MBRX stock, go to TipRanks’ Stock Analysis page.